Remove tag dr-b
article thumbnail

Can gene therapies for haemophilia defend their high price tags?

Pharmaceutical Technology

A fair price for CSL Behring’s haemophilia B treatment etranacogene dezaparvovec would be between $2.93–2.96 Haemophilia A is caused by insufficient levels of the clotting protein factor VIII, while patients with haemophilia B lack adequate factor IX levels. million price tag. million ($1.8 million at the time).

article thumbnail

Grand Rounds October 20, 2023: A National Initiative to Eliminate Hepatitis C in the United States – Why This Matters to Clinical Trialists (Rachael L. Fleurence, PhD, MSc; Joshua M. Sharfstein, MD)

Rethinking Clinical Trials

PCORnet has been an important resource by executing a query to identify the volume of HCV tests conducted by participating health systems and the number of co-infections with Hepatitis B virus. A manuscript is under development. The current trends of Hepatitis C epidemiology in the U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet

The Pharma Data

Dr. Ralf Clemens , Chairman of the Scientific Advisory Board for Clover’s COVID-19 Vaccine Program said, “This phase 1 dose-finding and adjuvant justification study demonstrated the potential of Clover’s adjuvanted vaccine candidates to bring added value to the global portfolio of COVID-19 vaccines. —- End —-.

article thumbnail

Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate

The Pharma Data

Dr. Richard Hatchett , Chief Executive Officer of CEPI, commented: “To end the acute phase of this pandemic, and to control the virus in the longer term, the world needs multiple safe and effective vaccines which can be deployed in a range of populations and countries. About Trimer-Tag© Technology. About CpG 1018.

article thumbnail

Clover Biopharmaceuticals Announces Positive Phase 1 Data for its Adjuvanted S-Trimer COVID-19 Vaccine Candidates

The Pharma Data

Utilizing Clover’s proprietary Trimer-Tag © technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate. About Trimer-Tag © Technology. Trimer-Tag © is an innovative drug development platform which allows the production of novel, covalently-trimerized fusion proteins.

article thumbnail

Company Spotlight: Cue Biopharma Innovates in the Immunotherapy Space with its Immuno-STAT Platform

XTalks

In 2017, the US FDA approved a CAR-T cell treatment for young adults and children with B-cell ALL. In speaking about Cue Biopharma’s mission and vision, Dr. Suri told Xtalks that the company was formed at the intersection of two very core fields in the space – one of them being immunology, and the other being rational protein engineering. “The

Protein 98
article thumbnail

Pharma By The Numbers: A Retrospective Look at the Industry and 20 Years of Xtalks History

XTalks

Just last year, the FDA approved a one-time gene therapy treatment for hemophilia B priced at $3.5 According to Dr. John K. In addition, nearly half of all new drugs launched between 2020 and 2021 came with a price tag of $150,000 per year, or more. million, making it the most expensive drug in the world.